Arvinas reported Q3 2021 financial results, including revenues of $9.3 million and a net loss of $46.8 million. The company highlighted its collaboration with Pfizer and advancements in its clinical-stage programs, particularly ARV-471 and ARV-110.
Initiated Phase 1b combination trial with ARV-110 and abiraterone for mCRPC.
Completed global collaboration with Pfizer, receiving $650 million upfront and a $350 million equity investment.
Cash, cash equivalents, restricted cash and marketable securities were $1,549.0 million as of September 30, 2021.
Intends to initiate the Phase 1b combination study with everolimus, potentially as part of a planned umbrella study with multiple combination agents with Pfizer, as well as the neoadjuvant study, in 2022.
Arvinas anticipates several milestones, including presenting data from ARV-471 and ARV-110 trials, initiating Phase 3 trials for ARV-471, and announcing Phase 1 data for ARV-766.
Analyze how earnings announcements historically affect stock price performance